An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Vanderbilt researchers have identified and characterized inhibitors of an enzyme that synthesizes lipid signaling molecules with roles in energy balance, inflammation and addiction.

A multidisciplinary team from Vanderbilt University Medical Center and Columbia University has demonstrated that injured human donor lungs declined for transplant can be recovered by cross-circulation between the human lung and a xenogeneic host.

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

The IVY Research Network has completed initial studies evaluating the epidemiology of COVID-19 in health care workers and patients.

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Bacterial invasion of vaginal cells sets up a protective niche and a reservoir for recurrent urinary tract infections, Vanderbilt researchers demonstrated.